Eldelumab
Sign in to saveEldelumab (alternative identifier BMS-936557) is a fully human monoclonal antibody (type IgG1 kappa) that targets chemokine (C-X-C motif) ligand 10 (CXCL10)/Interferon-γ-inducible protein-10 (IP-10) designed for the treatment of Crohn's disease and ulcerative colitis.
In the Vinony graph
Vinony's link graph records 253 inbound references to Eldelumab, and connects out to monoclonal antibody, lumiliximab and human.
It is catalogued under topics including Chemical pages without DrugBank identifier, Chemicals that do not have a ChemSpider ID assigned and Drugs developed by Bristol Myers Squibb.
Vinony links it to 5 Wikipedia language editions.
Wikidata facts
- Subclass of
- chemical compound
Show 2 more facts
- chemical formula
- C₆₅₀₂H₁₀₀₂₄N₁₇₃₆O₂₀₂₆S₄₈
- subject has role
- monoclonal antibody
via Wikidata · CC0
~1 min read
Encyclopedic overview
1 sectionsContents
- References
Eldelumab (alternative identifier BMS-936557) is a fully human monoclonal antibody (type IgG1 kappa) that targets chemokine (C-X-C motif) ligand 10 (CXCL10)/Interferon-γ-inducible protein-10 (IP-10) designed for the treatment of Crohn's disease and ulcerative colitis.
This drug was developed by Bristol-Myers Squibb and Medarex.
Excerpted from Wikipedia’s “Eldelumab” article, available under the CC BY-SA 4.0 licence.